SFDA Issues Med Device Irregularity Penalty Rules, Effective 2013
This article was originally published in PharmAsia News
China’s State FDA will implement its recently issued administrative penalty rules for pharma and medical device irregularities starting in 2013.
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.